JP2011252020A5 - - Google Patents

Download PDF

Info

Publication number
JP2011252020A5
JP2011252020A5 JP2011179129A JP2011179129A JP2011252020A5 JP 2011252020 A5 JP2011252020 A5 JP 2011252020A5 JP 2011179129 A JP2011179129 A JP 2011179129A JP 2011179129 A JP2011179129 A JP 2011179129A JP 2011252020 A5 JP2011252020 A5 JP 2011252020A5
Authority
JP
Japan
Prior art keywords
dosage form
buprenorphine
withdrawal syndrome
kit
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011179129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011252020A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011252020A publication Critical patent/JP2011252020A/ja
Publication of JP2011252020A5 publication Critical patent/JP2011252020A5/ja
Pending legal-status Critical Current

Links

JP2011179129A 2003-07-25 2011-08-18 依存性退薬症状の治療 Pending JP2011252020A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49040703P 2003-07-25 2003-07-25
US60/490,407 2003-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006521307A Division JP2007500134A (ja) 2003-07-25 2004-07-26 依存性退薬症状の治療

Publications (2)

Publication Number Publication Date
JP2011252020A JP2011252020A (ja) 2011-12-15
JP2011252020A5 true JP2011252020A5 (https=) 2012-11-01

Family

ID=34115390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006521307A Pending JP2007500134A (ja) 2003-07-25 2004-07-26 依存性退薬症状の治療
JP2011179129A Pending JP2011252020A (ja) 2003-07-25 2011-08-18 依存性退薬症状の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006521307A Pending JP2007500134A (ja) 2003-07-25 2004-07-26 依存性退薬症状の治療

Country Status (28)

Country Link
US (1) US8637073B2 (https=)
EP (1) EP1646328B1 (https=)
JP (2) JP2007500134A (https=)
KR (1) KR100829492B1 (https=)
CN (1) CN1829482B (https=)
AT (1) ATE375149T1 (https=)
AU (1) AU2004261182B2 (https=)
BR (1) BRPI0412931A (https=)
CA (1) CA2530005C (https=)
CY (1) CY1107262T1 (https=)
DE (1) DE602004009449T2 (https=)
DK (1) DK1646328T3 (https=)
EA (1) EA009921B1 (https=)
ES (1) ES2295929T3 (https=)
GE (1) GEP20125454B (https=)
HR (1) HRP20070476T3 (https=)
IL (1) IL173346A (https=)
IS (1) IS2630B (https=)
MA (1) MA28004A1 (https=)
MX (1) MXPA06000991A (https=)
NO (1) NO333189B1 (https=)
NZ (1) NZ545505A (https=)
PL (1) PL1646328T3 (https=)
PT (1) PT1646328E (https=)
SI (1) SI1646328T1 (https=)
UA (1) UA81056C2 (https=)
WO (1) WO2005011579A2 (https=)
ZA (1) ZA200510069B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297073A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
SI1646328T1 (sl) 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
BRPI0616788A2 (pt) * 2005-09-30 2011-07-05 Tti Ellebeau Inc sistemas, dispositivos e métodos de transferência de fármaco de modo transdérmico, e métodos que empregam agonista opióide e/ou antagonista opóide
EP2259780A2 (en) * 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
US8163731B2 (en) * 2008-08-20 2012-04-24 Rhodes Technologies Method and dosage regimens for eliminating a chemical substance in blood
WO2011116243A1 (en) 2010-03-17 2011-09-22 Method Products, Inc. Liquid cleaning compositions with lower freezing point
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
TW201307553A (zh) 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸(dha)及其他長鏈多元不飽和脂肪酸(lc-pufa)之技術
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
DK3400066T3 (da) * 2016-01-08 2021-10-18 Ohio State Innovation Foundation Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN107648234A (zh) * 2017-08-04 2018-02-02 中国人民解放军第二军医大学 一种治疗吗啡成瘾戒断症状的阿片类药物组合物
WO2019199704A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
AU2020342591A1 (en) * 2019-09-02 2022-03-03 Camurus Ab Formulations and treatment methods
MX2023009055A (es) * 2021-02-01 2024-01-05 Clear Scient Inc Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos.
EP4568672A2 (en) * 2022-08-12 2025-06-18 Bioventures, Llc Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
DE3939376C1 (https=) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
JPH06183956A (ja) * 1992-12-24 1994-07-05 Teisan Seiyaku Kk 安定な貼付用の製剤
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
WO2003079945A1 (en) 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
AU2003297073A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
SI1646328T1 (sl) 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti

Similar Documents

Publication Publication Date Title
JP2011252020A5 (https=)
JP2007500134A5 (https=)
JP2013173796A5 (https=)
JP2011511071A5 (https=)
JP2012193216A5 (https=)
JP2010525050A5 (https=)
JP2016517434A5 (https=)
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
JP2010520183A5 (https=)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2015522015A5 (https=)
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
JP2022028788A5 (https=)
CN102648279B (zh) 用于治疗药物诱发的手足综合征的组合物与方法
JP2016505050A5 (https=)
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2013540734A5 (https=)
CA2525202A1 (en) Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza
JP2009539916A5 (https=)
AU2019385373A1 (en) Application of chidamide in combination with R-CHOP, and drug combination
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP2010523660A5 (https=)
CN104147036B (zh) 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用